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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the 10th of a series of 16 reviews that have been prepared as background for advice from the
WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on integrating values and consumers in guideline development.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and
relevant methodological research. We reviewed the titles of all citations and retrieved abstracts and full text articles if
the citations appeared relevant to the topic. We checked the reference lists of articles relevant to the questions and used
snowballing as a technique to obtain additional information. We did not conduct a full systematic review ourselves. Our
conclusions based on the available evidence, consideration of what WHO and other organisations are doing and logical
arguments.
Key questions and answers: We did not find a systematic review of methods for integrating values in guidelines, but
we found several systematic reviews that dealt with related topics.
Whose values should WHO use when making recommendations?
• Values, the relative importance or worth of a state or consequences of a decision (outcomes relating to benefits, harms,
burden and costs), play a role in every recommendation. Ethical considerations, concepts that determine what is right,
also play a role.
• The values used in making recommendations should reflect those of the people affected. Judgements should be explicit
and should be informed by input from those affected (including citizens, patients, clinicians and policy makers).
• When differences in values may lead to different decisions or there is uncertainty about values, this should also be
explicit. If differences in values are likely to affect a decision, such that people in different setting would likely make
different choices about interventions or actions based on differences in their values, global recommendations should be
explicit in terms of which values were applied and allow for adaptation after incorporating local values.
How should WHO ensure that appropriate values are integrated in recommendations?
• All WHO guideline groups should uniformly apply explicit, transparent and clearly described methods for integrating
values.
• WHO should consider involving relevant stakeholders if this is feasible and efficient.
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• WHO should develop a checklist for guidelines panels to help them to ensure that ethical considerations relevant to
recommendations are addressed explicitly and transparently.
How should users and consumers be involved in generating recommendations?
• Including consumers in groups that are making global recommendations presents major challenges with respect to the
impossibility of including a representative spectrum of consumers from a variety of cultures and settings. Nonetheless,
consideration should be given to including consumers in groups who are able to challenge assumptions that are made
about the values used for making recommendations, rather than represent the values of consumers around the world.
• WHO should establish a network to facilitate involvement of users.
• Draft recommendations should be reviewed by consumers, who should be asked explicitly to consider the values that
were used.
How should values be presented in recommendations?
• Recommendations should include a description of how decisions were made about the relative importance of the
consequences (benefits, harms and costs) of a decision.
• Values that influence recommendations should be reported along with the research evidence underlying
recommendations.
• When differences in values would lead to different decisions or there is important uncertainty about values that are
critical to a decision, this should be flagged and reflected in the strength of the recommendation.
• Adaptable guideline templates that allow for integration of different values should be developed and used when 
differences in values are likely to be critical to a decision.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the 10th of a series of 16 reviews
that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to
WHO on how to achieve this.
Utilities, health state preferences or values are the desira-
bility or preference that individuals exhibit for a particular
health state [1]. Individuals usually assign less value to
and have less preference for more impaired health states
(e.g. death or dependency after a stroke) compared to
other health states (e.g. full health or having a very mild
stroke without serious sequela). In this document we will
use the terms "values" to refer to the relative worth or
importance of a health state or consequences (benefits,
harms and costs) of a decision. It is primarily this concept
of values that we focus on here.
Ethical or moral values also play a role in making health
care recommendations [2-4]. These refer to concepts of
what is right based on philosophical, humanistic or reli-
gious considerations. Ethical values can vary among indi-
viduals within a society and across societies or culture,
and may influence recommendations and the implemen-
tation of recommendations. We will refer to these as ethi-
cal considerations.
Several formal methods exist to measure values in health-
care [5,6]. The principle methods are based on direct util-
ity instruments including the standard gamble, time-trade
off and visual analogue scales [5,6]. Direct preference-
based instruments generate a value score for respondents'
current health state or hypothetical states, typically on a
0.0 to 1.0 scale where 0.0 indicates dead and 1.0 indicates
full health. Indirect methods offer alternatives to direct
assessments and include multi-attribute utility tools and
transformations based on quality of life assessments [7-
10]. Multi-attribute utility tools ask respondents to
describe their health state, and the value of that health
state is calculated using a developed formula representing
preferences of the general population. The Euroquol,
Quality of Well-Being Index, and the Health Utilities
Index are examples of this approach [9-11]. Transforma-
tions from generic health related quality of life tools uti-
lize modelling techniques that transform quality of life
scores into values [8]. Ranking scales and qualitative
methods compliment these methods [6]. However, the
application of their results is complicated by the fact that
the reproducibility between the different methods is poor
and each of the methods has strength and limitations.
Values play a role in every recommendation, either explic-
itly or implicitly. For instance patients who suffered anHealth Research Policy and Systems 2006, 4:22 http://www.health-policy-systems.com/content/4/1/22
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idiopathic deep venous thrombosis (DVT) usually receive
treatment with adjusted dose warfarin for one year to pre-
vent recurrent DVT and pulmonary embolism [12]. Con-
tinuing on standard-intensity warfarin beyond the
treatment of one year will reduce his absolute risk for
recurrent DVT by more than 7% per year for several years
[13]. The burdens of treatment include taking a warfarin
pill daily, keeping dietary intake of vitamin K constant,
monitoring the intensity of anticoagulation with blood
tests, and living with the increased risk of both minor and
major bleeding. Patients who are very averse to a recurrent
DVT would consider the benefits of avoiding DVT worth
the downsides of taking warfarin. Other patients are likely
to consider the benefit not worth the harms and burden.
Another example refers to the different values patients
with atrial fibrillation and their clinicians place on the
adverse consequences of stroke and gastrointestinal bleed
[14]. A third example relates to a health care recommen-
dation about the combination of chemotherapy and radi-
otherapy versus radiotherapy alone in unresectable,
locally advanced non-small cell lung cancer [15,16].
Compared with radiotherapy alone, the combination of
chemotherapy and radiotherapy reduces the risk for death
corresponding to a mean gain in life expectancy of a few
months [15], but increases harm and burden related to
chemotherapy. Thus, considering the values and prefer-
ences patients would place on the small survival benefit in
view of the harms and burdens, guideline panels may
offer a weak recommendation despite the high quality of
the available evidence. Generally, there is agreement that
the values that are used for comparing the relative benefits
and downsides of interventions should be explicit [17-
20].
In this paper we addressed the following questions:
￿ Whose values should WHO use when making recom-
mendations?
￿ How should WHO ensure that appropriate values are
integrated in recommendations?
￿ How should users and consumers be involved in gener-
ating recommendations?
￿ How should values be presented in recommendations?
Questions related to identifying important outcomes,
group composition and equity considerations are
addressed in other papers in this series [21-23].
What WHO is doing now
The Guidelines for WHO Guidelines suggests that end
users, and patients specifically, should be represented on
guideline panels [24]. However, review of selected WHO
guidelines did not yield information about the inclusion
of end users or patients in guideline groups or the use of
other methods to ensure appropriate integration of values
and consumer involvement. The fact that WHO makes
global recommendations presents challenges for obtain-
ing appropriate representation of values, because values
may differ across different cultures and settings.
What other organisations are doing?
A number of guideline developers have invited individu-
als who could represent and understand the perspectives
of stakeholders, including consumers [25]. However, in a
recent survey of organizations and specialty societies that
develop guidelines only approximately 25% regularly
involved consumers in the process [26]. In another survey
of 18 prominent organizations that develop guidelines
approximately 50% regularly involved patients [27].
The UK National Institute for Health and Clinical Excel-
lence (NICE) has adopted a very comprehensive approach
to involving patients and consumers and has formed a
patient involvement unit aiming to involve patients and
carers in the development of individual clinical guidelines
[20,28]. NICE consumer involvement can be categorized
into four broad areas:
1) Stakeholder consultation
Organisations can register and comment at any stage dur-
ing the development process. They can nominate patient
groups and participate and comment on the development
of a guideline at every stage from the suggestion of guide-
line topics, drafting of scopes, development and initial
drafting of guidelines, to the second consultation draft.
2) Direct input
NICE committees and working groups are expected to
include at least two members who play a crucial role by
providing a patient/carer perspective to their discussions
and decisions. They may be patients, carers or patient
advocates. Vacancies are publicised via national patient
and carer organisations, on a website or via the national
press.
3) Indirect input
Examples include focus groups with patients, patient writ-
ten testimonials and video-taped interviews with patients
that were presented to a technology appraisal committee.
4) Dissemination of NICE guidance to and by patients
All NICE guidance is produced in versions written for
patients, carers and the public. Copies can be downloadedHealth Research Policy and Systems 2006, 4:22 http://www.health-policy-systems.com/content/4/1/22
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from the NICE website or printed copies can be obtained
by telephoning the NHS Response line. Patient organisa-
tions play an increasingly significant role in helping NICE
disseminate its guidance to individual patients and carers
and providing feedback.
The Scottish Intercollegiate Guidelines Network (SIGN)
involves patients and patient representatives in the guide-
line development process. For each guideline, SIGN aims
to search for evidence about patient important outcomes
after having identified a guideline topic, but this is not
done consistently (R. Habour, personal communication).
SIGN also aims to include patient representatives and
guideline users in the process at all stages during the
development process [17]. The UK National Health Sys-
tem (NHS) Health Technology Assessment program also
systematically involves public advocates in their work [29-
32]. Various speciality societies describe that representa-
tion of consumers on guideline panels (at least one mem-
ber) is required which is often described as representation
by a patient advocacy group [33].
The Cochrane Collaboration, which produces systematic
reviews, but does not make recommendations, has made
consumer involvement an integral part of its work of pro-
ducing and disseminating systematic reviews and demon-
strated the feasibility of international consumer
involvement projects. In 1998 approximately two thirds
of Cochrane Collaboration review groups had consumer
involvement [34]. There is also a Cochrane Consumers
Network [35], which helps to provide consumer input
into developing Cochrane reviews.
Methods
The methods used to prepare this review are described in
the introduction to this series [36]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We reviewed existing guide-
lines for guidelines to identify processes for integrating
consumer values and consumer involvement. We based
the current summary and recommendation on the work
of prominent developers of guidelines. We also searched
PubMed using "consumer" and "involvement" as search
terms (MESH headings/keywords) for systematic reviews.
We searched PubMed for systematic reviews on how
guideline groups integrate values and preferences using
the terms "guideline" and "values OR preferences OR util-
ities" (we identified 694 citations labelled as systematic
reviews). We also searched the Cochrane library, Method-
ology registry and database using the keywords "guide-
line" and ("values" or "preferences"). We searched
databases maintained by the Agency for Healthcare
Research and Quality (AHRQ, [37]) and the Guidelines
International Network (GIN, [38]), and reviewed infor-
mation obtained from various organizations and our own
files. We did not conduct a full systematic review. The
answers to the questions are our conclusions based on the
available evidence, consideration of what WHO and other
organisations are doing and logical arguments.
Findings
We did not find a systematic review of methods for inte-
grating values in guidelines, but we found one systematic
review that compared whether values differ between the
general population and patients [39]. Another systematic
review that focused on interventions to promote con-
sumer involvement in developing healthcare policy and
clinical practice guidelines did not find any comparative
studies of consumer involvement versus no consumer
involvement or of different ways of involving consumers
[40]. We identified systematic reviews dealing with indi-
rect evidence focusing on consumer involvement, for
example in research agenda setting [31]. One review
focused on involving patients in the planning and devel-
opment of health care and another systematic review
addressed which methods should be used to include the
views of the public in policy documents [6,41]. We also
found a review summarized values obtained by rating
scale, time-trade off and standard gamble for different dis-
ease states [42]. In addition, we identified several articles
that addressed whether patient values should be inte-
grated in clinical practice guidelines [43].
Whose values should WHO use when making 
recommendations?
Clinicians' values for health states differ from those of
patients and among different clinician groups [14,44]. For
example, the values physicians assign to stroke as an out-
come and to adverse consequences (e.g., gastrointestinal
bleeding) of treatment to prevent stroke in patients with
atrial fibrillation differ from those of patients [14]. The
values used in making recommendations should reflect
those of the people affected. While there is widespread
belief that values for health states also differ between
patients and the general public, this belief is not sup-
ported by the available evidence. A systematic review of
33 studies found that preferences for hypothetical health
states did not differ between patients and the public [39].
Since guidelines, for the most part, affect the use of lim-
ited public resources and, therefore, inevitably affect the
general public, WHO guidelines should consider societal
values and recognise when there may be important, legit-
imate differences in values across different cultures and
settings. Judgements should be explicit and should be
informed by input from those affected (including citizens,
patients, clinicians and policy makers). Representation of
all potentially relevant societies in groups developing glo-
bal recommendations is not feasible. If differences in val-Health Research Policy and Systems 2006, 4:22 http://www.health-policy-systems.com/content/4/1/22
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ues are likely to affect a decision, such that people in
different setting would likely make different choices about
interventions or actions based on differences in their val-
ues, global recommendations should be explicit in terms
of which values were applied and allow for adaptation
after incorporating local values. It may also be possible to
include consumers or other stakeholders in panels with
the primary responsibility of questioning assumptions
that are made about values, rather than representing the
values of any particular group.
We found discussions of ethical considerations in guide-
lines and health technology assessments [2-4], but we did
not find a systematic review of processes for addressing
ethical considerations systematically and transparently.
There is no standard way for doing this, although Hof-
mann has taken a step towards developing a practical
approach by identifying relevant questions that could be
asked in the context of health technology assessments [4].
How should WHO ensure that appropriate values are 
integrated in recommendations?
The evidentiary basis for appropriate identification and
representation of values in guideline development is lim-
ited. We did not identify a systematic review focusing on
different ways of including values in clinical practice
guidelines. A review by Ryan and colleagues focused on
public preferences for healthcare [6]. The authors con-
cluded that there was no single, best method to gain pub-
lic opinion. The method must be carefully chosen and
rigorously carried out in order to accommodate the ques-
tion being asked. They recommend conjoint-based meth-
ods (including ranking, rating and choice-based),
willingness to pay, standard gamble and time trade-off as
quantitative techniques and one-to-one interviews, focus
groups, Delphi technique and citizens' juries as qualita-
tive techniques. There were only a few studies that con-
ducted direct comparisons of methods at that time (up to
2000) and the review requires updating.
While the evidence about which method should be
adopted is inconclusive, all of the methods mentioned
above are acceptable. Methods that transform results of
generic health related quality of life instruments into
value scores can also be used but they have the disadvan-
tage of requiring calculations and are based on mathemat-
ical assumptions in developing transformation equations.
If data from primary research on societal or patient values
are used, guideline panels should make explicit how these
values were measured (e.g., they should specify whether a
visual analogue scale, standard gamble or other methods
were used).
Decision analysis and economic analyses are approaches
to explicitly integrating values into guidelines, which may
sometimes be useful [45]. Less formal methods include
representation on guideline panels and consultation with
consumers to inform judgements about the relative
importance of the benefits and downsides of interven-
tions based on rating scales. WHO guideline groups
should uniformly apply explicit, transparent and clearly
described methods for integrating values.
How should users and consumers be involved in generating 
recommendations?
Consumers should be part of guideline groups, be able to
contribute and be heard. Van Wersch and Eccles evaluated
a guideline development program [46]. They described
experience with three alternative methods of consumer
involvement in guideline development: a) incorporating
individual patients; b) a one off meeting with patients;
and c) incorporating a consumer advocate in the guide-
line development group. They concluded that consumers
should be involved in all stages of guideline development,
while acknowledging that this is not straightforward, that
there is no right way to accomplish this, and that more
research is required to optimize the process and out-
comes.
Indirect evidence about the involvement of consumers
comes from studies evaluating the involvement of con-
sumers in research priority setting. Oliver and colleagues
systematically reviewed different methods of consumer
involvement in research priority setting [31]. They con-
cluded that "what we know about the advantages and dis-
advantages of methods for involving consumers in agenda
setting rests on weak short-term evidence and almost
entirely speculative long-term evidence". Telford and col-
leagues used a Delphi approach to identify principles and
indicators of successful involvement of consumers in
research [47]. They identified eight principles for the suc-
cessful involvement in research that could also be used by
WHO to ensure that consumers are adequately repre-
sented in guideline development projects (Table 1).
Any involvement of consumers requires a clear under-
standing of the evidence by consumers. Difficulties with
medical terminology or other jargon are an important
barrier to involvement. Well-informed and experienced
consumers are more likely to interact with the guideline
developers than those who are less informed or less famil-
iar with medical terminology or other jargon that is used.
A large number of studies have been conducted using a
variety of methods to elicit values for direct patient care
questions, but this literature is not well summarised and
it may be beyond the capacity of most groups developing
recommendations to systematically review the literature
relevant to the specific questions that they are addressing.
The review by Morimoto and Fukui is limited to directHealth Research Policy and Systems 2006, 4:22 http://www.health-policy-systems.com/content/4/1/22
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preference instruments and does not provide values for
the full spectrum of diseases for which WHO develops rec-
ommendations [42]. However, this and similar reviews
can provide some guidance because direct elicitation of
values from a representative sample of people is rarely fea-
sible.
WHO should consider developing a database or collabo-
rating with others to establish a database of evidence
about the relative values of common health outcomes
across different cultures and settings, which could be used
to inform the judgements made by groups making recom-
mendations.
How should values be presented in recommendations?
Values should always be considered in making recom-
mendations, although they do not always influence the
strength of a recommendation when they are uniformly
shared among patients and society. While values should
always be made explicit, WHO could restrict its presenta-
tion and labelling of values to those that are most impor-
tant for decision-making. These recommendations could
be flagged as being strongly influenced by values and
include a presentation of whose values they represent. In
particular recommendations should:
￿ Include a detailed description of how decisions were
made about the relative importance of the consequences
(benefits and downsides) of a decision. This should rou-
tinely be included in the methods section of a guideline.
￿ Values that influence recommendations should be
reported along with the research evidence underlying the
recommendations.
￿ When differences in values would lead to different deci-
sions or there is important uncertainty about values that
are critical to a decision, this should be flagged and
reflected in the strength of the recommendation.
￿ Adaptable guideline templates that allow for integration
of different values should be developed and used when
differences in values are likely to be critical to a decision
[48].
Discussion
There is no high quality research informing the choice of
whose values guideline panels should use or methods of
consumer involvement. NICE has set examples and made
advancements in involving consumers in guideline devel-
opment. Feedback from consumers involved in the NICE
process indicates that they value their involvement highly
[28].
Oliver and colleagues identified a number of studies that
evaluated different ways of involving consumers in
research priority setting [31]. While the results of their sys-
tematic review are informative, there are two important
limitations: 1) they focused on research priority setting
and 2) direct comparison of different methods of con-
sumer involvement were not found. A systematic review
Table 1: The principles and indicators of successful consumer involvement in NHS research (from Telford et al.) [37]
Principle Indicator(s)
1 The roles of consumers are agreed between the researchers and consumers 
involved in the research
• The roles of consumers in the research were documented
2 Researchers budget appropriately for the costs of consumer involvement in 
research
• Researchers applied for funding to involve consumers in the research
• Consumers were reimbursed for their travel costs
• Consumers were reimbursed for their indirect costs (e.g. carer costs)
3 Researchers respect the differing skills, knowledge and experience of consumers • The contribution of consumers-skills, knowledge and experience were included in 
research reports and papers
4 Consumers are offered training and personal support, to enable them to be 
involved in research
• Consumers – training needs related to their involvement in the research were 
agreed between consumers and researchers
• Consumers had access to training to facilitate their involvement in the research
• Mentors were available to provide personal and technical support to consumers
5 Researchers ensure that they have the necessary skills to involve consumers in the 
research process
• Researchers ensured that their own training needs were met
• in relation to involving consumers in the research
6 Consumers are involved in decisions about how participants are both recruited and 
kept informed about the progress of the research
• Consumers gave advice to researchers on how to recruit participants to the 
research
• Consumers gave advice to researchers on how to keep participants informed about 
the progress of the research
7 Consumer involvement is described in research reports • The involvement of consumers in the research reports and publications was 
acknowledged
• Details were given in the research reports and publications
• of how consumers were involved in the research process
8 Research findings are available to consumers, in formats and in language they can 
easily understand
• Research findings were disseminated to consumers involved in the research in 
appropriate formats (e.g. large print, translations, audio, Braille)
• The distribution of the research findings to relevant
• consumer groups was in appropriate formats and easily understandable language
• Consumers involved in the research gave their advice on the choice of methods 
used to distribute the research findingsHealth Research Policy and Systems 2006, 4:22 http://www.health-policy-systems.com/content/4/1/22
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of comparative studies of methods for involving consum-
ers in developing health care policy, research, clinical
practice guidelines and patient information found five
randomised trials, but none of these were relevant to
informing decisions about how best to involve consumers
in developing health care recommendations [40].
Further work
We have identified a number of unresolved questions that
require systematic reviews and additional research. A sys-
tematic review to evaluate the differences in values
between consumers/patients and clinicians or experts is
needed. Experimental work is needed that compares dif-
ferent strategies of consumer involvement in guideline
development to evaluate whether more resource intensive
approaches that include detailed methods to elicit and
include values lead to different recommendations or other
important differences.
A database of values assigned to specific health states may
also facilitate the development of guidelines. Such a data-
base should include information on the methods used
and these methods should be explicitly stated when val-
ues are included in recommendations. While additional
research on acceptable methods for eliciting values for
inclusion in guidelines is required, one barrier is the phil-
osophical and personal investment of researchers in par-
ticular methods. None of these available methods has
demonstrated its superiority to others. Thus, achieving
consensus on current best practice, that could be modified
when new evidence become available, might be helpful.
Development of an appropriate checklist of questions that
address key ethical considerations would help to ensure
that these were addressed more systematically and facili-
tate reporting of important considerations, so that these
were made more transparent. Adaptable guideline tem-
plates that allow for integration of different values should
be developed and used when differences in values are
likely to be critical to a decision [49]. Finally, better ways
of communicating value-sensitive information need to be
investigated.
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